Benjamin Besse: Impressive benefit for Lenvatinib-Pembrolizumab in patients with thymic carcinoma and B3 thymoma

Estela Rodriguez shared a post by Benjamin Besse, Head of Clinical Research at Gustave Roussy, on X:

“ESMO24 ThymicCa: Lenvatinib+Pembro meaningful ORR23% mPFS 14.9 mo in 2+ line of therapy.”

Quoting Benjamin Besse’s post:

“Impressive benefit for Lenvatinib-Pembrolizumab in pts with thymic carcinoma and B3 thymoma.

ORR 23.3% and mPFS 14.9m are unexpected in 2nd line or more. Lenvatinib dose matters in a subgroup analysis.

Congratulations Jordi Remon ESMO24.”

Source: Estela Rodriguez/X and Benjamin Besse/X

Estela (Estelamari)  Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.